BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Michelfelder S, Parsons J, Bohlender LL, Hoernstein SNW, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker EL, Häffner K. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders. J Am Soc Nephrol 2017;28:1462-74. [PMID: 27932477 DOI: 10.1681/ASN.2015070745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential. J Am Soc Nephrol 2018;29:1141-53. [PMID: 29335241 DOI: 10.1681/ASN.2017070738] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
2 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bohlender LL, Parsons J, Hoernstein SNW, Bangert N, Rodríguez-jahnke F, Reski R, Decker EL. Unexpected Arabinosylation after Humanization of Plant Protein N-Glycosylation. Front Bioeng Biotechnol 2022;10:838365. [DOI: 10.3389/fbioe.2022.838365] [Reference Citation Analysis]
4 Poppelaars F, Goicoechea de Jorge E, Jongerius I, Baeumner AJ, Steiner MS, Józsi M, Toonen EJM, Pauly D; SciFiMed consortium. A Family Affair: Addressing the Challenges of Factor H and the Related Proteins. Front Immunol 2021;12:660194. [PMID: 33868311 DOI: 10.3389/fimmu.2021.660194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Meng Y, Chen D, Qiu N, Mine Y, Keast R, Meng S, Zhu C. Comparative N-glycoproteomic analysis of Tibetan and lowland chicken fertilized eggs: Implications on proteins biofunction and species evolution. J Food Biochem 2021;:e14006. [PMID: 34859904 DOI: 10.1111/jfbc.14006] [Reference Citation Analysis]
6 Kerr H, Herbert AP, Makou E, Abramczyk D, Malik TH, Lomax-Browne H, Yang Y, Pappworth IY, Denton H, Richards A, Marchbank KJ, Pickering MC, Barlow PN. Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice. Front Immunol 2021;12:681098. [PMID: 34054871 DOI: 10.3389/fimmu.2021.681098] [Reference Citation Analysis]
7 Top O, Milferstaedt SWL, van Gessel N, Hoernstein SNW, Özdemir B, Decker EL, Reski R. Expression of a human cDNA in moss results in spliced mRNAs and fragmentary protein isoforms. Commun Biol 2021;4:964. [PMID: 34385580 DOI: 10.1038/s42003-021-02486-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Bohlender LL, Parsons J, Hoernstein SNW, Rempfer C, Ruiz-Molina N, Lorenz T, Rodríguez Jahnke F, Figl R, Fode B, Altmann F, Reski R, Decker EL. Stable Protein Sialylation in Physcomitrella. Front Plant Sci 2020;11:610032. [PMID: 33391325 DOI: 10.3389/fpls.2020.610032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ramezaniaghdam M, Nahdi ND, Reski R. Recombinant Spider Silk: Promises and Bottlenecks. Front Bioeng Biotechnol 2022;10:835637. [DOI: 10.3389/fbioe.2022.835637] [Reference Citation Analysis]
10 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
11 Zeerleder S, Engel R, Zhang T, Roem D, van Mierlo G, Wagenaar-Bos I, van Ham SM, Wuhrer M, Wouters D, Jongerius I. Sugar Matters: Improving In Vivo Clearance Rate of Highly Glycosylated Recombinant Plasma Proteins for Therapeutic Use. Pharmaceuticals (Basel) 2021;14:54. [PMID: 33440845 DOI: 10.3390/ph14010054] [Reference Citation Analysis]
12 Top O, Parsons J, Bohlender LL, Michelfelder S, Kopp P, Busch-Steenberg C, Hoernstein SNW, Zipfel PF, Häffner K, Reski R, Decker EL. Recombinant Production of MFHR1, A Novel Synthetic Multitarget Complement Inhibitor, in Moss Bioreactors. Front Plant Sci 2019;10:260. [PMID: 30949184 DOI: 10.3389/fpls.2019.00260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
13 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
14 Kerr H, Wong E, Makou E, Yang Y, Marchbank K, Kavanagh D, Richards A, Herbert AP, Barlow PN. Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation. J Biol Chem 2017;292:13345-60. [PMID: 28637873 DOI: 10.1074/jbc.M117.795088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
15 Ruiz-Molina N, Parsons J, Müller M, Hoernstein SNW, Bohlender LL, Pumple S, Zipfel PF, Häffner K, Reski R, Decker EL. A synthetic protein as efficient multitarget regulator against complement over-activation. Commun Biol 2022;5:152. [PMID: 35194132 DOI: 10.1038/s42003-022-03094-5] [Reference Citation Analysis]
16 Ruiz-molina N, Parsons J, Schroeder S, Posten C, Reski R, Decker EL. Process Engineering of Biopharmaceutical Production in Moss Bioreactors via Model-Based Description and Evaluation of Phytohormone Impact. Front Bioeng Biotechnol 2022;10:837965. [DOI: 10.3389/fbioe.2022.837965] [Reference Citation Analysis]
17 Yang Y, Denton H, Davies OR, Smith-Jackson K, Kerr H, Herbert AP, Barlow PN, Pickering MC, Marchbank KJ. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. J Am Soc Nephrol 2018;29:1649-61. [PMID: 29588430 DOI: 10.1681/ASN.2017091006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
18 Gilmore AC, Zhang Y, Cook HT, Lavin DP, Katti S, Wang Y, Johnson KK, Kim S, Pickering MC. Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains. Kidney Int 2021;99:396-404. [PMID: 33129896 DOI: 10.1016/j.kint.2020.09.028] [Reference Citation Analysis]